Case Study: Novo Nordisk Squeezed by U.S. Anti-Corruption and Russian Anti-Monopoly Requirements
When the Danish pharmaceutical company stopped using distributors in part because they didn’t fit anti-corruption compliance requirements, Russian authorities hit the drug-maker with a fine.
Incorrect password.
This story is exclusively for members of the
JUST ANTI-CORRUPTION COMMUNITY
Subscribe







